242 episodes

Dr. Stephen Liu and Dr. Narjust Florez host Lung Cancer Considered, the podcast of The International Association for the Study of Lung Cancer (IASLC). IASLC is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 6,500 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Visit www.iaslc.org for more information.

Lung Cancer considered is funded in part by AstraZeneca, Genentech, Daiichi Sankyo, Inc., and Takeda

Lung Cancer Considered IASLC

    • Science
    • 4.6 • 23 Ratings

Dr. Stephen Liu and Dr. Narjust Florez host Lung Cancer Considered, the podcast of The International Association for the Study of Lung Cancer (IASLC). IASLC is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 6,500 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Visit www.iaslc.org for more information.

Lung Cancer considered is funded in part by AstraZeneca, Genentech, Daiichi Sankyo, Inc., and Takeda

    LCC In Greek

    LCC In Greek

    LCC In Greek by IASLC

    • 1 hr
    Clinical Discussion in the Management of Early-Stage NSCLC

    Clinical Discussion in the Management of Early-Stage NSCLC

    In this episode of Lung Cancer Considered, host Dr. Narjust Florez moderates a discussion on the management of early-stage disease, with an eye toward applying conclusions from trials such as the ADAURA and the recent ESMO and ELCC data about perioperative chemo-immunotherapy.

    • 54 min
    LCC: The Management Of CNS Metastases In Driver Negative NSCLC

    LCC: The Management Of CNS Metastases In Driver Negative NSCLC

    Description: Host Dr. Narjust Florez and two esteemed international clinicians discuss the unique characteristics of CNS metastases in patients with non-small cell lung cancer and small cell lung cancer.

    Guest: Dr. Sarah Goldberg is an Associate Professor of Medicine in the section of Medical Oncology at the Yale School of Medicine. She is the Division Chief of Thoracic Oncology, the Research Director for the Center for Thoracic Cancers, and the Associate Program Director for the Medical Oncology-Hematology Fellowship Program at Yale

    Guest: Dr. Ernest Nadal is a medical oncologist and the director of Thoracic Tumors Section at the Catalan Institute of Oncology, an Associate Professor at the University of Barcelona, a vital member of the Spanish Lung Cancer Group and an expert in clinical trial development and interest in response and use of immune checkpoint inhibitors for the management of CNS metastases.

    • 47 min
    Lung Cancer Considered in Romanian

    Lung Cancer Considered in Romanian

    Continuing our series of podcasts in different world languages, this episode focuses on lung cancer research and treatment in Romanian.

    Host: Mihaela Aldea, MD PhD
    Thoracic Oncology and Precision Medicine Group
    Department of Medical Oncology
    Gustave Roussy, Villejuif, France

    Guest: Dr Cristina Ligia Cebotaru, Institute of Oncology 'Prof Dr Ion Chiricuta' Department of Radiotherapy-Medical Oncology, Cluj Napoca

    Guest: Dr. Paul Kubelac, Department of Medical Oncology, Institute of Oncology Cluj-Napoca-Romania

    • 35 min
    The Importance of Waiting for Biomarker Results in NSCLC

    The Importance of Waiting for Biomarker Results in NSCLC

    Biomarkers are essential in lung cancer treatment, but they remain underutilized. In addition, clinicians and patients have to wait for those results before starting therapy. In this episode of Lung Cancer Considered, host Dr. Stephen Liu guides a discussion about biomarkers and some of the challenges and issues they create.

    • 50 min
    LCC In Italian--First-Line Treatment Options for EGFR Mutant NSCLC

    LCC In Italian--First-Line Treatment Options for EGFR Mutant NSCLC

    This episode of Lung Cancer Considered discusses first-line treatment options for EGFR mutant NSCLC, in Italian.

    Guest: Dr. Jessica Menis is a thoracic medical oncologist with expertise in early-phase trials and drug development from Azienda Ospedaliera Universitaria Integrata Verona. Jessica, welcome to the podcast.


    Guest: Professor Filippo de Marinis is from Istituto Europeo di Oncologia, where he is Direttore della Divisione di Oncologia Toracica, and the president of Associazione Italiana Oncologia Toracica.

    • 47 min

Customer Reviews

4.6 out of 5
23 Ratings

23 Ratings

TBobo ,

Episode on Immunotherapy

Really enjoyed the conversation between these oncologist. They seem to be great doctors who really care for their patients are working for the best solutions they know of.

It was also interesting to see their blind spots. The great thing about immunotherapy is slowly opening the door between integrative oncology and traditional oncology. These guys don’t get into it but they are asking the right questions.

1) What can be combined with immunotherapy?
2) What can be done to prevent side effects of traditional treatment?
3) What things can be done to both enhance traditional treatments and lower side effects?

Naturopath and integrative doctors know many possible answer to these questions based on case studies and their personal experience. Things that will never get a $500 million dollar set of clinical trials, but have worked for patient after patient.

- Infrared Saunas to detox from chemo and have much fewer side effects (combined with other detox techniques).
- High Dose Melatonin to reduce radiation damage - with early limited clinical trials as evidence.
- Hypothermia for combining with immunotherapy.
- Proton radiation on a different schedule than normal to promote immunotherapy (3 day on 4 day off cycle seems to work better than the traditional 5 day on 2 day off, to give the immune system a chance to do its thing).
- Micro-biome research to enhance immunotherapy both through diet, supplements, and even fecal transplants.
- Natural products and off-label drugs to help limit the metabolism of cancer to slow down its growth, keep it from mutating to new food sources, and ultimately make chemo and other treatments more effective, as well as providing a much greater quality of life for the patients.

If transitional oncology would do two things, immunotherapy will advance much faster.
1) Eat a bite of humble pie and realize integrative doctors and oncologist have some answers, and start having conversations with them.
2) Realize their training and education failed them in the areas of nutrition, health, and epi-genetics.
3) Realize the level of corruption in the FDA, NIH, and pharmaceutical companies, with at least 350 MILLION dollars being passed under the table to individual for the last 10 years. This seems to be greatly hampering the rules being used to approve new drugs - creating measure that have nothing to do with patient survival - but do help big pharma profits. So after realizing there is this level of corruption and unethical behavior, it is illogical and unethical to continue to just rely on these groups to produce the “cures” for cancer.

It is going to take people doing and trying things have have more ethical motivations, writing papers, doing smaller trials, and forcing innovation solutions down the throat of the FDA with them kicking an screaming.

Then someone needs to do something to STOP the unethical price gouging of the Pharma on immunotherapy. The are obviously coordinating their pricing in a cornered market. Again unethical and unjustified. We need to vote for political leaders who can pass some laws to bring this into account.

And all the Cancer patient advocacy groups that are SILENT on these issues need to be shamed into action… even though they get big donations from big Pharma too.

DrFLC ,

Fantastic for doctors, nurses, patients

Great conversations on all things lung cancer.

yeoohaz ,

:)

great info!

Top Podcasts In Science

Hidden Brain
Hidden Brain, Shankar Vedantam
Radiolab
WNYC Studios
Ologies with Alie Ward
Alie Ward
StarTalk Radio
Neil deGrasse Tyson
Something You Should Know
Mike Carruthers | OmniCast Media
Short Wave
NPR

You Might Also Like

Lung Cancer Update
Dr Neil Love
Two Onc Docs
Sam and Karine
NEJM This Week
NEJM Group
The Curbsiders Internal Medicine Podcast
The Curbsiders Internal Medicine Podcast
The Happiness Lab with Dr. Laurie Santos
Pushkin Industries
Hidden Brain
Hidden Brain, Shankar Vedantam